Recent MTVA News
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 • PR Newswire (US) • 03/12/2026 01:01:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 • PR Newswire (US) • 02/13/2026 01:31:00 PM
- MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel • PR Newswire (US) • 02/04/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/27/2026 09:01:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 09:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2026 09:05:21 PM
- MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option • PR Newswire (US) • 01/16/2026 09:01:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/16/2026 01:36:51 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/16/2026 05:15:12 AM
- MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering • PR Newswire (US) • 01/15/2026 02:32:00 PM
- Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)] • Edgar (US Regulatory) • 01/15/2026 02:12:56 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/12/2026 10:22:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 10:22:53 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/05/2026 10:04:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 01:32:38 PM
- MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile • PR Newswire (US) • 01/05/2026 01:30:00 PM
- MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference • PR Newswire (US) • 12/29/2025 01:31:00 PM
- MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement • PR Newswire (US) • 12/22/2025 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:01:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/02/2025 01:46:21 PM
- MetaVia Inc. Announces 1-for-11 Reverse Stock Split • PR Newswire (US) • 12/02/2025 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:29:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2025 02:01:20 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
